Skip to main content
Glama

Compare Entities

compare_entities
Read-onlyIdempotent

"Compare X and Y" / "X vs Y" / "X versus Y" / "which is bigger / better / larger / more profitable" / "rank these companies" / "head to head" — side-by-side comparison of 2–5 companies or drugs in ONE parallel call. ALWAYS PREFER over sequential single-pack lookups when comparing entities. type="company" pulls LATEST 10-K revenue + net income + cash + long-term debt from SEC EDGAR/XBRL (off-calendar fiscal years handled correctly — AAPL Sep, NVDA Jan, etc.). type="drug" pulls FAERS adverse-event counts, FDA approval counts, active trial counts. Results sorted by primary metric so "largest" / "most" / "biggest" reads off the top of the response. Returns paired data + pipeworx:// citation URIs per entity. Replaces 8–15 sequential lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valuesYesFor company: 2–5 tickers/CIKs (e.g., ["AAPL","MSFT"]). For drug: 2–5 names (e.g., ["ozempic","mounjaro"]).

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. First observed

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

The description enriches the read-only/idempotent annotations with specific behavioral details: it pulls 10-K financial metrics from SEC EDGAR/XBRL, handles off-calendar fiscal years, sorts results by primary metric, and returns paired data with citation URIs. This goes well beyond the annotations and provides actionable expectations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness5/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is dense yet efficient. It front-loads with user intent examples, then covers data sources, behavior, and output, finishing with an ROI statement ('Replaces 8–15 sequential lookups'). Every sentence adds value without redundancy.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

Given the moderate complexity (2 params, no output schema), the description fully compensates by stating what is returned (paired data, citation URIs), how results are sorted, and the data source specifics. This is sufficient for an agent to invoke the tool and interpret results correctly.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters3/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

The input schema already covers both parameters with descriptions, enumeration for 'type', and constraints for 'values'. The description adds some context (e.g., what metrics are pulled for each type) but does not significantly change parameter understanding. With 100% schema coverage, the baseline of 3 is appropriate.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description clearly states the tool performs side-by-side comparisons of 2–5 companies or drugs in one parallel call. It uses specific verbs like 'compare', 'rank', and 'head to head', and explicitly distinguishes itself from sequential single-pack lookups, making its purpose and scope unmistakable.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description provides explicit example queries ('Compare X and Y', 'which is bigger/better', 'rank these companies') and specifies when this tool should be preferred over sequential lookups. It also differentiates behavior between company and drug types, offering clear usage context.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.5/5.0
Disambiguation2/5

Several tools have overlapping purposes: ask_pipeworx and ask_pipeworx_beta are currently identical, deep_research overlaps with ask_pipeworx, and discover_tools/suggest_questions both serve a discovery role. The extremely detailed descriptions help, but the boundaries between meta-tools and research tools are genuinely confusing, especially with 34 tools in one namespace.

Naming Consistency2/5

Naming is a mix of bare verbs (get, search, recall), nouns (affiliation, entity_profile, recent_changes), and verb_noun phrases (resolve_entity, compare_entities, validate_claim). Some families are consistent (polymarket_*), but overall there is no uniform convention or prefix scheme, making the set feel arbitrary.

Tool Count2/5

34 tools is well above the 25+ threshold for 'too many.' While the broad data-platform scope explains some of the count, many tools are meta-utilities (feedback, trending, memory, subscription management) and there are near-duplicate variants (three ask_pipeworx forms, six Polymarket tools) that inflate the surface.

Completeness4/5

For a data-research platform the surface is impressively complete: lookup, grounded verification, entity profiles, comparisons, claim checking, subscription lifecycle, memory, and tool discovery are all covered. Minor gaps exist (e.g., no direct general-purpose web fetch, and ROR lacks create/update, which is acceptable for a curated registry), but agents should rarely hit dead ends.